Drug Profile
Filorexant
Alternative Names: MK-6096Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Amides; Antidepressants; Antimigraines; Piperidines; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic neuropathies; Insomnia; Major depressive disorder; Migraine
Most Recent Events
- 30 Aug 2015 No recent reports of development identified - Phase-II for Diabetic neuropathies in USA (PO)
- 30 Aug 2015 No recent reports of development identified - Phase-II for Major depressive disorder (Adjunctive treatment, Recurrent) in USA (PO)
- 30 Aug 2015 No recent reports of development identified - Phase-II for Migraine (Prevention) in USA (PO)